For ICB, programmed cell death-ligand 1 (PD-L1) expression on tumour or immune cells and tumour mutation burden (TMB) were approved by the US Food and Drug Administration (FDA) to predict ICB response in diverse tumour types [9, 10]. The gene discussed is CD274; the disease is neoplasm.